Strategy

Non-surgical medical aesthetic market reached $8.4B globally in 2016, with facial aesthetics and skin rejuvenation enjoying sustainable double-digit growth and accounting for over $2B market.

Toxins and Hyaluronic Acid fillers paralyze muscles and inflate the skin respectively, often causing the widely reported unnatural “done” look.

Collagen fibers function as the skins’ primary support structure; their degradation over time is the principal cause of skin ageing. Directly restoring the skins collagen is an obvious solution that currently doesn’t exist in the market.

Launching the only Bio-Dermal Restoration portfolio will give EternoGen Aesthetics a highly differentiated market entry that will meet the ever increasing physician and consumer needs for instant, natural and lasting results without using foreign materials.

The EternoGen Aesthetics portfolio will innovate the tiring injectable market.

Naturally Disrupt the Stagnant Toxin / Filler Market

EternoGen Aesthetics will leverage recognized key influencers, academic pre-clinical and clinical data, new media and accelerated experience to drive the adoption curve.

Experienced and focused full service distributors have been recruited in target markets to provide 1st line sales representation to core customers. Patient interest and advocacy will be driven on-line and channeled to RPC customers.